论文部分内容阅读
人们早已认识到性激素可影响肝脏许多功能及其形态结构。近年来,特别引起人们关注的是,临床及实验证明雌激素可影响正常和肿瘤情况下的肝细胞增生。应用抗雌激素药可降低肝脏雌激素受体水平,从而达到姑息治疗肝癌的目的。本文用抗雌激素药它莫西芬(tamoxifen)对进展性肝癌进行对照性治疗研究。病人和方法不能切除的肝癌合并肝硬化患者32例。其中酒精性肝硬化14例,乙肝相关性肝硬化7例,原发性胆汁性肝硬化2例,自身免疫慢性肝硬化1例,隐匿性肝硬化8例。将患者分为两组:治疗组给予它莫西芬30mg/d 16例,对照组不用药16例。治疗组与对照组年龄
It has long been recognized that sex hormones can affect many functions of the liver and its morphological structure. In recent years, there is particular concern that clinical and experimental evidence shows that estrogen can affect hepatocyte proliferation in both normal and tumor situations. Application of anti-estrogen drugs can reduce the level of liver estrogen receptor, so as to achieve the purpose of palliative treatment of liver cancer. In this paper, anti-estrogen drug tamoxifen (tamoxifen) for the control of advanced liver cancer research. Thirty-two patients with hepatocellular carcinoma and cirrhosis who can not be removed by the patients and methods. Including alcoholic cirrhosis in 14 cases, hepatitis B-related cirrhosis in 7 cases, 2 cases of primary biliary cirrhosis, autoimmune chronic liver cirrhosis in 1 case, occult cirrhosis in 8 cases. The patients were divided into two groups: the treatment group received tamoxifen 30mg / d 16 cases, the control group without medication in 16 cases. Treatment group and control group age